Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies (Q39770397)

14 September 2017

Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies (English)

1 reference

14 September 2017

1 reference

3

Michael Weller

1 reference

14 September 2017

1

David A Reardon

1 reference

14 September 2017

4

Joerg Christian Tonn

1 reference

14 September 2017

Bart Neyns

2

1 reference

14 September 2017

Louis Burt Nabors

series ordinal

5

1 reference

14 September 2017

Roger Stupp

series ordinal

6

1 reference

14 September 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

14 September 2017

1 reference

14 September 2017

7

1 reference

14 September 2017

3

1 reference

14 September 2017

339-354

1 reference

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

14 September 2017

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

21 January 2018

1 reference

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

21 January 2018

1 reference

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 January 2018

1 reference

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

21 January 2018

1 reference

The biomechanical integrin

21 January 2018

1 reference

Src kinase activity is required for integrin alphaVbeta3-mediated activation of nuclear factor-kappaB.

21 January 2018

1 reference

NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival

21 January 2018

1 reference

Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells

21 January 2018

1 reference

Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis

21 January 2018

1 reference

The adaptor protein Crk connects multiple cellular stimuli to the JNK signaling pathway

21 January 2018

1 reference

Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors

21 January 2018

1 reference

Targeting integrins in malignant glioma

21 January 2018

1 reference

Integrins in cancer: biological implications and therapeutic opportunities

21 January 2018

1 reference

Stimulation of glioma-cell migration by laminin and inhibition by anti-alpha3 and anti-beta1 integrin antibodies

21 January 2018

1 reference

Migration arrest in glioma cells is dependent on the alphav integrin subunit

21 January 2018

1 reference

Integrins in angiogenesis and lymphangiogenesis

21 January 2018

1 reference

Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation

21 January 2018

1 reference

A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature

21 January 2018

1 reference

Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation

21 January 2018

1 reference

Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells

21 January 2018

1 reference

Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells

21 January 2018

1 reference

Integrin alpha 6 regulates glioblastoma stem cells

21 January 2018

1 reference

Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma

21 January 2018

1 reference

Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature

21 January 2018

1 reference

Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery.

21 January 2018

1 reference

Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells

21 January 2018

1 reference

Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist

21 January 2018

1 reference

Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro

21 January 2018

1 reference

Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency

21 January 2018

1 reference

Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice

21 January 2018

1 reference

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

21 January 2018

1 reference

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.

21 January 2018

1 reference

MGMT: its role in cancer aetiology and cancer therapeutics

21 January 2018

1 reference

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity

21 January 2018

1 reference

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

Recent advances in the treatment of malignant astrocytoma

21 January 2018

1 reference

Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas.

21 January 2018

1 reference

Spatial expression of VEGF-A in human glioma.

21 January 2018

1 reference

Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma.

21 January 2018

1 reference

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

21 January 2018

1 reference

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

21 January 2018

1 reference

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 January 2018

1 reference

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

Bevacizumab and recurrent malignant gliomas: a European perspective.

21 January 2018

1 reference

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

21 January 2018

1 reference

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

21 January 2018

1 reference

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.

21 January 2018

1 reference

Structural alterations of the epidermal growth factor receptor gene in human gliomas

21 January 2018

1 reference

alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.

21 January 2018

1 reference

Expression of adhesion molecules and extracellular matrix proteins in glioblastomas: relation to angiogenesis and spread

21 January 2018

1 reference

The extracellular matrix of gliomas: modulation of cell function

21 January 2018

1 reference

Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion

21 January 2018

1 reference

Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.

21 January 2018

1 reference

Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study

21 January 2018

1 reference

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma

21 January 2018

1 reference

Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins

21 January 2018

1 reference

Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography

21 January 2018

1 reference

Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand

21 January 2018

1 reference

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

21 January 2018

1 reference

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

21 January 2018

1 reference

Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins

21 January 2018

1 reference

N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists

21 January 2018

1 reference

alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.

21 January 2018

1 reference

Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models

21 January 2018

1 reference

Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.

21 January 2018

1 reference

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial

21 January 2018

1 reference

Will integrin inhibitors have proangiogenic effects in the clinic?

21 January 2018

1 reference

Phase II Evaluations of Cilengitide in Asymptomatic Patients with Androgen-Independent Prostate Cancer: Scientific Rationale and Study Design

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.11.8

1 reference

14 September 2017

1 reference